Humana Inc vs JPMorgan Chase & Co — how do they compare? Humana Inc trades at $444.98 (market cap $47.61B), while JPMorgan Chase & Co trades at $332.56 (market cap $876.09B). The key difference: JPMorgan Chase & Co is far larger — about 18.4× Humana Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (2%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and JPMorgan Chase & Co for 127 Days on average.
| HUM | JPM | |
|---|---|---|
Market Cap | $47.61B | $876.09B |
Volume | 1,827,332 | 6,651,143 |
Sector | Health | Financials |
52-Week High | $409.85 | $365.18 |
52-Week Low | $163.67 | $282.84 |
Typical Hold Time | 53 Days | 127 Days |
Enterprise Value | $54.97B | $1.81T |
Dividend Yield | 0.89% | 2% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
JPMorgan Chase (JPM) trades at $329.58, down 0.51% on the day, with a bearish technical signal. The stock shows strong fundamentals, with a P/E of 14.12 and net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 was a miss. Analyst consensus is a Moderate Buy with a $373.18 price target, implying potential upside. Cash flow trends show significant financing activities offsetting negative operating cash flows.
The outlook for JPM is positive based on robust profitability and analyst support, but risks include volatile cash flows, geopolitical tensions affecting banking sectors, and CEO warnings on economic challenges. The stock's current price near support at $327 suggests a potential entry point for long-term investors, though near-term bearish technicals warrant caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →